Advertisement

HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications

      Highlights

      • Trastuzumab deruxtecan showed to prolong survival in HER2-low breast cancer (BC).
      • No data exist on the clinical role of HER2-low expression in inflammatory BC (IBC).
      • We found more ER-expressing tumours among stage III HER2-low (versus HER2-zero) IBC.
      • As in non-IBC, no clear prognostic role emerged for HER2-low expression in IBC.
      • Our results do not support HER2-low as a distinct subtype of IBC.

      Abstract

      Background

      HER2)-low expression is a predictive biomarker for novel anti-HER2 antibody-drug conjugates. However, little is known about its clinical significance in inflammatory breast cancer (IBC).

      Methods

      Patients diagnosed with HER2-negative IBC between December 1999 and December 2020 were identified from the Dana-Farber Cancer Institute IBC registry. Patients were divided into HER2-low (IHC 1+ or 2+/ISH–) and HER2-zero (IHC 0), comparing clinicopathologic features and disease outcomes between the two subgroups.

      Results

      The study included 276 patients. Among patients with stage III (n = 209) and stage IV (n = 67) IBC, 54% and 39% had HER2-low tumours, respectively. Oestrogen receptor (ER)-expressing tumours were more common in patients with HER2-low versus HER2-zero stage III IBC (65% versus 38%, p < 0.01). Among stage III patients undergoing surgery (n = 182), pathologic complete response (pCR) rates were higher for HER2-zero versus HER2-low IBC (11% versus 6%, OR: 1.8, 95%CI:0.6–5.3), but minimal differences persisted when separately analysing pCR by ER status. Similar invasive disease-free survival (iDFS) outcomes were observed among ER-positive HER2-zero versus HER2-low IBC (48-month iDFS: 63% versus 63%, HR: 1.10, 95%CI:0.57–2.13) and ER-negative HER2-zero versus HER2-low IBC (48-month iDFS: 28% versus 25%, HR: 1.19, 95%CI:0.69–2.04). Differences in overall survival (OS) were small, both among ER-positive HER2-zero versus HER2-low IBC (48-month OS: 80% versus 81%, HR: 0.82, 95%CI:0.39–1.73) and ER-negative HER2-zero versus HER2-low IBC (48-month OS: 34% versus 47%, HR: 1.34, 95%CI: 0.74–2.41).

      Conclusions

      Marginal differences in clinicopathologic features and outcomes were observed in HER2-low versus HER2-zero IBC when controlling for ER status, not supporting the definition of HER2-low as a distinct subtype of IBC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chang S.
        • Parker S.L.
        • Pham T.
        • Buzdar A.U.
        • Hursting S.D.
        Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992.
        Cancer. Jun 15 1998; 82: 2366-2372
        • Hance K.W.
        • Anderson W.F.
        • Devesa S.S.
        • Young H.A.
        • Levine P.H.
        Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.
        J Natl Cancer Inst. Jul 6 2005; 97: 966-975https://doi.org/10.1093/jnci/dji172
        • Lim B.
        • Woodward W.A.
        • Wang X.
        • Reuben J.M.
        • Ueno N.T.
        Inflammatory breast cancer biology: the tumour microenvironment is key.
        Nat Rev Cancer. Aug 2018; 18: 485-499https://doi.org/10.1038/s41568-018-0010-y
        • Kertmen N.
        • Babacan T.
        • Keskin O.
        • et al.
        Molecular subtypes in patients with inflammatory breast cancer; a single center experience.
        J Buon. Jan-Feb 2015; 20: 35-39
        • Cortés J.
        • Kim S.K.
        • Chung W.
        • et al.
        Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study [abstract].
        Ann Oncol. 2021; 32 (Abstract LBA1)https://doi.org/10.1016/annonc/annonc741
        • Hurvitz S.
        • Kim S.-B.K.
        • Chung W.-P.
        • et al.
        Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03 [abstract].
        Cancer Res. 2022; 82 (Abstract GS3-01)https://doi.org/10.1158/1538-7445.SABCS21-GS3-01
        • Tarantino P.
        • Hamilton E.
        • Tolaney S.M.
        • et al.
        HER2-Low breast cancer: pathological and clinical landscape.
        J Clin Oncol. Jun 10 2020; 38: 1951-1962https://doi.org/10.1200/JCO.19.02488
        • Modi S.
        • Park H.
        • Murthy R.K.
        • et al.
        Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study.
        J Clin Oncol. Jun 10 2020; 38: 1887-1896https://doi.org/10.1200/JCO.19.02318
        • Banerji U.
        • van Herpen C.M.L.
        • Saura C.
        • et al.
        Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
        Lancet Oncol. Aug 2019; 20: 1124-1135https://doi.org/10.1016/S1470-2045(19)30328-6
        • Wang J.
        • Liu Y.
        • Zhang Q.
        • et al.
        RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies.
        J Clin Oncol. 2021; 39 (1022-1022)https://doi.org/10.1200/JCO.2021.39.15_suppl.1022
        • Modi S.
        • Jacot W.
        • Yamashita T.
        • et al.
        Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
        N Engl J Med. 2022; (DOI: 10.1056/NEJMoa2203690)https://doi.org/10.1056/NEJMoa2203690
        • Denkert C.
        • Seither F.
        • Schneeweiss A.
        • et al.
        Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
        Lancet Oncol. Aug 2021; 22: 1151-1161https://doi.org/10.1016/s1470-2045(21)00301-6
        • Agostinetto E.
        • Rediti M.
        • Fimereli D.
        • et al.
        HER2-Low breast cancer: molecular characteristics and prognosis.
        Cancers. 2021; 13: 2824
        • Schettini F.
        • Chic N.
        • Brasó-Maristany F.
        • et al.
        Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
        NPJ Breast Cancer. Jan 4 2021; 7: 1https://doi.org/10.1038/s41523-020-00208-2
        • Tarantino P.
        • Gandini S.
        • Nicolò E.
        • et al.
        Evolution of low HER2 expression between early and advanced-stage breast cancer.
        Eur J Cancer. Mar 2022; 163: 35-43https://doi.org/10.1016/j.ejca.2021.12.022
        • Wolff A.C.
        • Hammond M.E.H.
        • Allison K.H.
        • et al.
        Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update.
        J Clin Oncol. Jul 10 2018; 36: 2105-2122https://doi.org/10.1200/JCO.2018.77.8738
        • Hein A.
        • Hartkopf A.D.
        • Emons J.
        • et al.
        Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
        Eur J Cancer. 2021; 155: 1-12https://doi.org/10.1016/j.ejca.2021.06.033
        • Tarantino P.
        • Jin Q.
        • Tayob N.
        • et al.
        Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer.
        JAMA Oncol. 2022; (DOI:10.1001/jamaoncol.2022.2286)https://doi.org/10.1001/jamaoncol.2022.2286
        • Won H.S.
        • Ahn J.
        • Kim Y.
        • et al.
        Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
        Breast Cancer Res. 2022; 24: 22https://doi.org/10.1186/s13058-022-01519-x
        • Gampenrieder S.P.
        • Rinnerthaler G.
        • Tinchon C.
        • et al.
        Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
        Breast Cancer Res. 2021; 23: 112https://doi.org/10.1186/s13058-021-01492-x
        • Horisawa N.
        • Adachi Y.
        • Takatsuka D.
        • et al.
        The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
        Breast Cancer. Oct 7 2021; https://doi.org/10.1007/s12282-021-01303-3
        • de Moura Leite L.
        • Cesca M.G.
        • Tavares M.C.
        • et al.
        HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
        Breast Cancer Res Treat. Nov 2021; 190: 155-163https://doi.org/10.1007/s10549-021-06365-7
        • Mutai R.
        • Barkan T.
        • Moore A.
        • et al.
        Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
        Breast. Dec 2021; 60: 62-69https://doi.org/10.1016/j.breast.2021.08.016
        • Jacot W.
        • Maran-Gonzalez A.
        • Massol O.
        • et al.
        Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers.
        Cancers. 2021; 13: 6059
        • Alves F.R.
        • Gil L.
        • Vasconcelos de Matos L.
        • et al.
        Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer.
        Cureus. Feb 2022; 14e22330https://doi.org/10.7759/cureus.22330
        • Tan R.S.Y.C.
        • Ong W.S.
        • Lee K.-H.
        • et al.
        HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
        BMC Med. 2022; 20: 105https://doi.org/10.1186/s12916-022-02284-6
        • Schalper K.A.
        • Kumar S.
        • Hui P.
        • Rimm D.L.
        • Gershkovich P.
        A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
        Arch Pathol Lab Med. Feb 2014; 138: 213-219https://doi.org/10.5858/arpa.2012-0617-OA
        • Fernandez A.I.
        • Liu M.
        • Bellizzi A.
        • et al.
        Examination of low ERBB2 protein expression in breast cancer tissue.
        JAMA Oncol. Apr 1 2022; 8: 1-4https://doi.org/10.1001/jamaoncol.2021.7239
        • Dieras V.
        • Deluche E.
        • Lusque A.
        • et al.
        Trastuzumab deruxtecan for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY) [abstract].
        Cancer Res. 2022; 82 (Abstract PD8-02)https://doi.org/10.1158/1538-7445.SABCS21-PD8-02
        • Boyraz B.
        • Ly A.
        Discerning subsets of breast cancer with very low and absent HER2 protein expression.
        Hum Pathol. Jun 4 2022; https://doi.org/10.1016/j.humpath.2022.05.019
        • Nuciforo P.
        • Radosevic-Robin N.
        • Ng T.
        • Scaltriti M.
        Quantification of HER family receptors in breast cancer.
        Breast Cancer Res. 2015; 17: 53https://doi.org/10.1186/s13058-015-0561-8
        • Dawood S.
        • Lei X.
        • Dent R.
        • et al.
        Survival of women with inflammatory breast cancer: a large population-based study.
        Ann Oncol. Jun 2014; 25: 1143-1151https://doi.org/10.1093/annonc/mdu121
        • Jiao D.
        • Zhang J.
        • Zhu J.
        • et al.
        Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
        BMC Cancer. 2021; 21 (2021/02/06 https://doi.org/10.1186/s12885-021-07855-z): 138